UBE2N and acute myeloid leukemia: To identify the mechanistic basis for UBE2N dependency in AML, we prioritized the top targets from the ubiquitin-enrichment screen (Figure 3D), the total proteome analysis (Figure 3F), and the CRISPRa screen (Figure 3H).